Dezlorid-M 10 Tablets

babies: not applicable. lactating mother: desloratadine, montelukast sodium tablet is unsafe in lactating mothers.
studies suggest that this medication may cause toxicity to the baby. pregnancy: consult your doctor before using this medication.
driving: this medication may affect your ability to drive. do not drive if any symptoms occur.
alcohol: desloratadine, montelukast sodium tablet is used with caution with alcohol as it may increase your drowsiness kidney: this medication should be used with caution in patients with kidney disease. you may need a dose adjustment.
liver: this medication should be used with caution in patients with liver disease. you may need a dose adjustment..

Nausea Diarrhea Dry mouth Vomiting Skin rash Flu-like symptoms Fatigue Headache.

DEZLORID-M tablet is used to treat runny nose, stuffy nose, sneezing, watery eyes and congestion or stuffiness caused due to Allergy, It works by preventing the action of chemical messengers which are responsible for causing allergic symptoms, swelling in the airways and nose respectively..

If you miss a dose, Take it as soon as possible. If It is near the time of the next dose, then skip the missed dose.
Take the prescribed dose on your regular time daily. Don't double the dose to catch up with the missed dose..

• dazIt is prescribed to treat runny nose, stuffy nose, sneezing, watery eyes and congestion or stuffiness caused due to Allergy • Avoid drinking alcohol as It may lead to an increase in your drowsiness with This medicine. • Do not drive as It may cause dizziness, which may affect your ability to drive • Do not Take this medication at least three days Before being for an Allergy test as It may affect the test results..

• desloratadine + pitolisant: concurrent use of these drugs results in decreased pitolisant efficacy. • montelukast sodium + dasabuvir: concurrent use of these drugs results in increased dasabuvir concentration.
• montelukast sodium + leflunomide/trimethoprim/pixantrone: concurrent use of these drugs results in increased exposure of cyp2c8 substrate. • montelukast sodium + gemfibrozil: concurrent use of these drugs results in elevated montelukast plasma concentration.
• montelukast sodium + phenobarbital/rifampicin: concurrent use of these drugs decreases montelukast's bioavailability. • montelukast sodium + prednisone: concurrent use of these drugs results in severe peripheral oedema..